This review selected TEM1 (score 9), VEGFR-1 (score 8), EGFR (score 8), VEGFR-2 (score 7), IGF-1R (score 7), PDGFRα (score 7), and CD40 (score 7) as the most promising cell surface-expressed biomarkers for tumor-specific NIRF imaging in STS, for which clinically available monoclonal antibodies are already present. This evidence concerns the gene PDGFRA and telomere syndrome.